Radiopharm - Model AVß6 - Integrin Radioactive Drugs

• AVβ6 is a strong and selective ligand for a cell surface protein called αvβ6-integrin. As such, it can accumulate in tissue areas characterized by high αvβ6-integrin levels
• There is compelling evidence that αvβ6-Integrin is found in many of the most challenging cancers, such as pancreatic carcinoma, cervical, head-and-neck and certain lung cancers
• AVβ6 offers an unparalleled performance for radiolabelling with Gallium-68
• AVβ6 is a highly promising clinical candidate for early detection of the aforementioned conditions by PET imaging
• Radiopharm Theranositcs plans to design & synthesise a number of conjugates for a therapeutic approach and enter clinical trials at the earliest opportunity

European Journal of Nuclear Medicine and Molecular Imaging – Image of the Month

• αvβ6-specific peptide
• PET/CT image of primary tumour in pancreatic head
• Pancreatic ductal carcinoma confirmed histologically
• Prominent signals are observed only in kidneys and urinary bladder due to renal excretion
• No relevant uptake is seen in lungs, stomach, liver and intestines
• Potential applications for fibrosis, PDAC and other carcinomas (head-and-neck squamous cell, lung adenocarcinoma, colon, cervical, mammary)